Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HR091506 vs Febuxostat in Gout with Hyperuricemia
NCT06414837Phase 3Not yet recruiting
- Sponsor
- Hengrui
- Start
- Jun 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of HR091506 in gout, hyperuricemia, sponsored by Hengrui. Planned start Jun 2024; status: not yet recruiting.
02
Drugs
HR091506
03
Conditions
gouthyperuricemia
Beyond the preview
Go deeper on NCT06414837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06414837.